Following the acquisition of Henlix Biotech and Tridem Pharma in the span of a week, Shanghai Fosun Pharmaceutical Group, the healthcare unit of Fosun International Ltd., achieved a new milestone, with its market cap at a record high of over CNY100bn on Nov. 6.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?